EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 692 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR NF1 Associated with More Cancer Types Than Previously Known April 20, 2021 Characterisation of KRAS, Including KRAS G12C, Mutations in Gastrointestinal and Metastatic... July 2, 2021 Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast... January 14, 2021 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 Load more HOT NEWS Holidays and Hope When a Loved One Has Advanced Cancer Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Mom Says Family Was Kicked Out Of Movie Theater Because Her... Oxaliplatin-Based Adjuvant Chemotherapy Shows Good Tolerance and Similar Time To Recurrence...
